Dr. Faderl Gives an Overview of Novel Therapies for AML

Stefan Faderl, MD
Published: Tuesday, Mar 25, 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Faderl believes that immunotherapies represent the area that will see the greatest expansion in hematologic malignancies. There has been much activity in FLT3-positive AMLs with novel inhibitors in combination with standard chemotherapies, though there is not much data available yet. Novel leukemia stem cell markers are interesting on a conceptual basis, though they may or may not hold promise, Faderl says.

Faderl says there is not a specific novel therapy that is a particular highlight.

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Faderl believes that immunotherapies represent the area that will see the greatest expansion in hematologic malignancies. There has been much activity in FLT3-positive AMLs with novel inhibitors in combination with standard chemotherapies, though there is not much data available yet. Novel leukemia stem cell markers are interesting on a conceptual basis, though they may or may not hold promise, Faderl says.

Faderl says there is not a specific novel therapy that is a particular highlight.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x